MX2015003192A - Composicion para su utilizacion como plasma de control anormal de la coagulacion de ensayos in vitro. - Google Patents

Composicion para su utilizacion como plasma de control anormal de la coagulacion de ensayos in vitro.

Info

Publication number
MX2015003192A
MX2015003192A MX2015003192A MX2015003192A MX2015003192A MX 2015003192 A MX2015003192 A MX 2015003192A MX 2015003192 A MX2015003192 A MX 2015003192A MX 2015003192 A MX2015003192 A MX 2015003192A MX 2015003192 A MX2015003192 A MX 2015003192A
Authority
MX
Mexico
Prior art keywords
composition
vitro assays
control plasma
coagulation control
abnormal coagulation
Prior art date
Application number
MX2015003192A
Other languages
English (en)
Other versions
MX362870B (es
Inventor
Jose Segui Borrell
Daniel Martorell Pena
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2015003192A publication Critical patent/MX2015003192A/es
Publication of MX362870B publication Critical patent/MX362870B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al sector del análisis clínico de la sangre y, más en particular, se refiere a una composición que comprende plasma humano, solución isotónica tamponada y ácido ferúlico para utilizar en el control anormal de la coagulación en ensayos de hemostasia, coagulación y fibrinolisis. Además, la presente invención se refiere a la utilización de ácido ferúlico en la preparación de un control anormal de plasma en ensayos de hemostasia.
MX2015003192A 2014-03-13 2015-03-12 Composición para su utilización como plasma de control anormal de la coagulación de ensayos in vitro. MX362870B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430343A ES2475492B1 (es) 2014-03-13 2014-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Publications (2)

Publication Number Publication Date
MX2015003192A true MX2015003192A (es) 2015-10-29
MX362870B MX362870B (es) 2019-02-20

Family

ID=51063211

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003192A MX362870B (es) 2014-03-13 2015-03-12 Composición para su utilización como plasma de control anormal de la coagulación de ensayos in vitro.

Country Status (11)

Country Link
US (1) US9482679B2 (es)
EP (1) EP2919014B1 (es)
JP (1) JP6215245B2 (es)
CN (1) CN104914256B (es)
AR (1) AR099753A1 (es)
AU (1) AU2015201260B2 (es)
BR (1) BR102015005628A8 (es)
CA (1) CA2883260C (es)
CL (1) CL2015000469A1 (es)
ES (2) ES2475492B1 (es)
MX (1) MX362870B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108169467B (zh) * 2017-11-27 2019-09-20 中国科学院苏州生物医学工程技术研究所 一种血栓弹力图仪质控品及其制备方法和应用
CN109239373A (zh) * 2018-08-15 2019-01-18 迪瑞医疗科技股份有限公司 一种组织因子酯化物试剂及其制备方法与应用
CN110346582B (zh) * 2019-07-15 2022-10-25 三诺生物传感股份有限公司 一种凝血复合质控品及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US6194394B1 (en) * 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
AU7137900A (en) * 1999-07-23 2001-02-13 Medical Analysis Systems, Inc. Stabilized coagulation control reagent and method of making same
CN103626653B (zh) * 2013-08-14 2015-06-24 河南大学 冬凌草促凝血有效成分及其制备方法和应用

Also Published As

Publication number Publication date
CN104914256A (zh) 2015-09-16
US20150260740A1 (en) 2015-09-17
US9482679B2 (en) 2016-11-01
MX362870B (es) 2019-02-20
CA2883260C (en) 2019-02-19
AU2015201260B2 (en) 2018-05-10
ES2475492A1 (es) 2014-07-10
BR102015005628A2 (pt) 2016-04-26
JP2015175850A (ja) 2015-10-05
ES2639445T3 (es) 2017-10-26
CL2015000469A1 (es) 2015-10-02
JP6215245B2 (ja) 2017-10-18
CA2883260A1 (en) 2015-09-13
CN104914256B (zh) 2018-04-03
ES2475492B1 (es) 2015-01-15
EP2919014A1 (en) 2015-09-16
BR102015005628A8 (pt) 2022-07-05
AR099753A1 (es) 2016-08-17
EP2919014B1 (en) 2017-08-16
AU2015201260A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
ZA201705114B (en) Cysteine protease
ZA201705113B (en) Cysteine protease
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
PE20170931A1 (es) Nuevas normalizaciones y dispositivos medicos para la preparacion de plasma rico en plaquetas (prp) o concentrado de medula osea (bmc) solos o combinados con acido hialuronico
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
IN2015DN01300A (es)
MY165124A (en) Semifluorinated alkane compositions
MX360564B (es) Análisis de coagulación de bajo volumen.
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
MX365713B (es) Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
MX358132B (es) Solucion de trombina y metodos de uso de esta.
PH12014501176A1 (en) Anticoagulant reversal agents
MX362870B (es) Composición para su utilización como plasma de control anormal de la coagulación de ensayos in vitro.
MX2015016603A (es) Composiciones de corticosteroides.
AU2013367193A8 (en) Wound healing accelerator
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112016027649A2 (pt) Proteínas prohemostáticas para o tratamento de hemorragia

Legal Events

Date Code Title Description
FG Grant or registration